WO2023275333A1 - Inhibitors of transglutaminases - Google Patents
Inhibitors of transglutaminases Download PDFInfo
- Publication number
- WO2023275333A1 WO2023275333A1 PCT/EP2022/068212 EP2022068212W WO2023275333A1 WO 2023275333 A1 WO2023275333 A1 WO 2023275333A1 EP 2022068212 W EP2022068212 W EP 2022068212W WO 2023275333 A1 WO2023275333 A1 WO 2023275333A1
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- compound
- cyclo
- methyl
- bicyclo
- och
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Ceased
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
- C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
- C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D213/72—Nitrogen atoms
- C07D213/75—Amino or imino radicals, acylated by carboxylic or carbonic acids, or by sulfur or nitrogen analogues thereof, e.g. carbamates
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
- A61K31/4375—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a six-membered ring having nitrogen as a ring heteroatom, e.g. quinolizines, naphthyridines, berberine, vincamine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4412—Non condensed pyridines; Hydrogenated derivatives thereof having oxo groups directly attached to the heterocyclic ring
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
- A61K31/443—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with oxygen as a ring hetero atom
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
- A61K31/4436—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a heterocyclic ring having sulfur as a ring hetero atom
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
- A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
- A61K31/444—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring heteroatom, e.g. amrinone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/445—Non condensed piperidines, e.g. piperocaine
- A61K31/45—Non condensed piperidines, e.g. piperocaine having oxo groups directly attached to the heterocyclic ring, e.g. cycloheximide
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/445—Non condensed piperidines, e.g. piperocaine
- A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
- A61K31/4545—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring hetero atom, e.g. pipamperone, anabasine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
- A61K31/4709—Non-condensed quinolines and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
- A61K31/4748—Quinolines; Isoquinolines forming part of bridged ring systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/4965—Non-condensed pyrazines
- A61K31/497—Non-condensed pyrazines containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/4995—Pyrazines or piperazines forming part of bridged ring systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/50—Pyridazines; Hydrogenated pyridazines
- A61K31/501—Pyridazines; Hydrogenated pyridazines not condensed and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/50—Pyridazines; Hydrogenated pyridazines
- A61K31/502—Pyridazines; Hydrogenated pyridazines ortho- or peri-condensed with carbocyclic ring systems, e.g. cinnoline, phthalazine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
- A61K31/5375—1,4-Oxazines, e.g. morpholine
- A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
- C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
- C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D213/72—Nitrogen atoms
- C07D213/74—Amino or imino radicals substituted by hydrocarbon or substituted hydrocarbon radicals
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
- C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
- C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D213/72—Nitrogen atoms
- C07D213/76—Nitrogen atoms to which a second hetero atom is attached
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
- C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
- C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D213/78—Carbon atoms having three bonds to hetero atoms, with at the most one bond to halogen, e.g. ester or nitrile radicals
- C07D213/81—Amides; Imides
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
- C07D405/12—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
- C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
- C07D409/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
- C07D413/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
- C07D417/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D453/00—Heterocyclic compounds containing quinuclidine or iso-quinuclidine ring systems, e.g. quinine alkaloids
- C07D453/02—Heterocyclic compounds containing quinuclidine or iso-quinuclidine ring systems, e.g. quinine alkaloids containing not further condensed quinuclidine ring systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/04—Ortho-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
- C07D487/08—Bridged systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D513/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00
- C07D513/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00 in which the condensed system contains two hetero rings
- C07D513/04—Ortho-condensed systems
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
- Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
- Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
Definitions
- the invention relates to novel inhibitors of transglutaminases, in particular transglutaminase 2, methods for their synthesis and to their use for the prophylaxis and treatment of diseases associated with transglutaminases, in particular transglutaminase 2.
- Transglutaminases are part of the class of transferases and according to EC nomenclature they are correctly designated as “protein-glutamine: amine g-glutamyl transferases” (EC 2.3.2.13). They link the e-amino group of the amino acid lysine and the g-glutamyl group of the amino acid glutamine forming an isopeptide bond while ammonia is released. In the absence of suitable amines and/or under certain conditions, deamidation of the glutamine may occur resulting in the corresponding glutamic acid.
- transglutaminases play an important role in many therapeutic areas such as the cardiovascular diseases (thrombosis and atherosclerosis), autoimmune diseases (celiac disease, Duhring-Brocq-disease, gluten ataxia), neurodegenerative diseases (Alzheimer’s disease, Parkinson’s disease, Huntington’s disease), dermatological diseases (ichthyosis, psoriasis, acne) as well as in wound healing and inflammatory diseases (e.g. tissue fibrosis) (J.M. Wodzinska, Mini-Reviews in medical chemistry, 2005, 5, 279 - 292).
- cardiovascular diseases thrombosis and atherosclerosis
- autoimmune diseases celiac disease, Duhring-Brocq-disease, gluten ataxia
- neurodegenerative diseases Alzheimer’s disease, Parkinson’s disease, Huntington’s disease
- dermatological diseases ichthyosis, psoriasis, acne
- wound healing and inflammatory diseases e.g. tissue
- Celiac disease a gluten intolerance, however, is one of the most important indications.
- Celiac disease is characterized by a chronic inflammation of the mucosa of the small intestine.
- the intestinal epithelium is successively destroyed after ingestion of gluten-containing food resulting in reduced absorption of nutrients which again has massive impact on the patients affected and is for example associated with symptoms such as loss of weight, anemia, diarrhea, nausea, vomiting, loss of appetite and fatigue. Due to these findings, there is a large demand for the development of a medicament for the treatment of celiac disease as well as of other diseases associated with tissue transglutaminase (transglutaminase 2, TG2, tTG).
- tissue transglutaminase is a central element during pathogenesis.
- the endogenous enzyme catalyses the deamidation of gluten/gliadin in the small intestinal mucosa and thus triggers the inflammatory response. Therefore inhibitors of tissue transglutaminase are suitable to be used as active agents for medication.
- Another very important group of indications for tissue transglutaminase inhibitors are fibrotic disorders. Fibrotic disorders are characterized by the accumulation of cross- linked extracellular matrix proteins. Diabetic nephropathy, cystic fibrosis, idiopathic pulmonary fibrosis, kidney fibrosis as well as liver fibrosis belong to the most important fibrotic disorders to be addressed with the compounds disclosed.
- US 9,434,763 B2 discloses pyridinone derivatives having a warhead comprising at least one acceptor-substituted double bond, such as a Michael System, as irreversible transglutaminase inhibitors.
- Alkylacetamido and arylacetamido pyridinones showed inhibitory activity regarding tissue transglutaminase TG2 in nanomolar range (IC50).
- US 11 ,072,634 B2 discloses reversible transglutaminase inhibitors comprising an aldehyde, a ketone, an a-ketoaldehyde, an a-ketoketone, an a-ketoacid, an a-ketoester, an a-ketoamide or a halogenmethylketone as warhead.
- the inhibitors showed inhibitory activity regarding tissue transglutaminase TG2 in nanomolar and micromolar range (IC50) ⁇
- the objective of the present invention is to provide novel, most probably irreversible inhibitors of transglutaminases, in particular transglutaminase 2 and methods for the synthesis of said inhibitors as well as several uses of these inhibitors.
- transglutaminase 2 tissue transglutaminase 2 or TG2.
- transglutaminase 2 tissue transglutaminase 2
- such chemical warhead moiety is particularly selected from irreversible warheads such as a,b-unsaturated-ketoester, a,b-unsaturated ketoamide and a,b- unsaturated-sulfone.
- the compounds of the present invention act as selective inhibitors of transglutaminase 2.
- L represents -L 1 - or -L 1 -L 2 -; preferably -L 1 -L 2 -;
- L 1 represents -CH 2 -, -CH 2 CH 2 -, -CH 2 CH 2 CH 2 - -CH 2 CO-, or -CH 2 CH 2 CO-;
- L 2 represents a bond, -NR N1 - -NR N1 CH 2 - -NR N1 CH 2 CH 2 - or -NR N1 CH(CH 3 )-,
- R 1 represents
- R 2 represents
- R a , R b , R c , R d , and R e represent independently of each other -H, -F, -Cl, -Br, -CN, -OH, -CH 3 , -CH 2 CH 3 ,, -CH 2 CH 2 CH 3 ,, -CH(CH 3 ) 2 , -CHF 2 , -CF 3 , -CH 2 CF3, -COCH 3 ,, -COCH 2 CH 3 ,, -CO 2 H, -CO 2 CH 3 ,, -CO 2 C 2 H 5 , -CONH 2 ,
- R 4 represents -R 5 , -OR 5 or -NR 6 R 7 ;
- R 5 represents -H, -CH 3 , -CH 2 CH 3 , -CH 2 CH 2 CH 3 , -CH(CH 3 ) 2 ,
- R 6 and R 7 represent independently of each other -H, -CH 3 , -CH 2 CH 3 ,
- R 8 , R 9 , R 10 , R 11 , R 12 , R 13 , and R 14 represent independently of each other -H, -F, -Cl, -Br, -I, -OH, -CN, -NO 2 , -CH 3 , -C 2 H 5 , -C 3 H 7 , -CH(CH 3 ) 2 , -C 4 H 9 ,
- R 8 and R 9 or R 9 and R 10 can form together one of the following five-membered or six-membered rings: or R 12 and R 13
- R N represents -H, -CH 3 , -C 2 H 5 , -C 3 H 7 , -CH(CH 3 ) 2 , -C 4 H 9 , -CH 2- CH(CH 3 ) 2 ,
- R N1 represent -H, -CH 3 , or -CH 2 CH 3 ; or a diastereomer, an enantiomer, a mixture of diastereomers, a mixture of enantiomers, a racemate, a solvate, a hydrate, or a pharmaceutically acceptable salt thereof.
- inhibition data were determined using the classical fluorescent transamidation assay (dansylcadaverine incorporation into methylated casein, DCC-assay) as described in BCichold et al. [BCichold, C.; Hils, M.; Gerlach, U.; Weber, J.; Pelzer, C.; Heil, A.; Aeschlimann, D.; Pasternack, R.
- ZED1227 The First-ln-Class Tissue Transglutaminase Inhibitor Undergoing Clinical Evaluation for the Treatment of Celiac Disease. Cells 2022, 11, 1667.
- inventive compounds of formula (I) rated “A” showed efficacies of about 250-fold higher compared to Ref. 3 (A8).
- Ref. 5 is more than 25-times less potent in comparison to compound 111-83 as evident from Table 1.
- 2-bicyclo[3.1 1]heptyl wherein R a , R b , R c , R d and R e have the same meanings as defined herein.
- 2-bicyclo[3.1.1 ]heptyl has the following structure: wherein R a and R b , have the same meanings as defined herein.
- the compound of the formula (I) has an irreversible warhead, such as a,b-unsaturated-ketoester, a,b-unsaturated ketoamide and a,b-unsaturated-sulfone.
- the compounds of the present invention act as selective inhibitors of transglutaminase 2.
- the present invention refers to the compounds of the formula (I) wherein
- L represents -L 1 - or -L 1 -L 2 - ; preferably -L 1 -L 2 -;
- L 1 represents -CH 2 -, -CH 2 CH 2 - -CH 2 CH 2 CH 2 -, -CH 2 CO-, or -CH 2 CH 2 CO-;
- L 2 represents a bond, -NR N1 - -NR N1 CH 2 - -NR N1 CH 2 CH 2 - or -NR N1 CH(CH 3 )-;
- R 1 represents or
- R 2 represents
- unsubstituted bicyclic residues can be substituted with 1 to 5 of the substituents R 9 -R 14 , and R N ; and preferably with 1 to 3 of the substituents R 11 - R 13 ;
- R a , R b , R c , R d , and R e represent independently of each other -H, -F, -Cl, -Br, -CN, -OH, -CH 3 , -CH 2 CH 3 ,, -CH 2 CH 2 CH 3 ,, -CH(CH 3 ) 2 , -CHF 2 , -CF 3, -CH 2 CF3, -COCH 3 ,, -COCH 2 CH 3 ,, -CO2H, -CO2CH 3 ,, -CO2C2H5, -CONH2,
- R 4 represents -R 5 , -OR 5 or -NR 6 R 7 ;
- R 5 represents -H, -CH 3 , -CH 2 CH 3 , -CH 2 CH 2 CH 3 , -CH(CH 3 ) 2 ,
- R 6 and R 7 represent independently of each other -H, -CH 3 , -CH 2 CH 3 , or -CH 2 CH 2 OCH 2 CH 3 ;
- R 8 , R 9 , R 10 , R 11 , R 12 , R 13 , and R 14 represent independently of each other -H, -F, -Cl, -Br, -I, -OH, -CN, -NO 2 , -CH 3 , -C 2 H 5 , -C 3 H 7 , -CH(CH 3 ) 2 , -C 4 H 9 ,
- R 8 and R 9 or R 9 and R 10 can form together one of the following five-membered or six-membered rings: or R 12 and R 13
- R N represents -H, -CH 3 , -C 2 H 5 , -C 3 H 7 , -CH(CH 3 ) 2 , -C 4 H 9 , -CH 2- CH(CH 3 ) 2 ,
- R N1 represent -FI, — CH 3 , or — CH 2 CH 3 ; or a diastereomer, an enantiomer, a mixture of diastereomers, a mixture of enantiomers, a racemate, a solvate, a hydrate, or a pharmaceutically acceptable salt thereof.
- R 2 represents preferably
- unsubstituted bicyclic residues can be substituted with 1 to 5 of the substituents R 9 -R 14 , and R N ; and preferably with 1 to 3 of the substituents R 11 - R 13 and the substituents R 9 - R 14 , and R N have the meanings as defined herein or as in claim 1.
- the unsubstituted bicyclic residues which can be substituted with 1 to 5 of the substituents R 9 - R 14 and R N have the following structure and the substituents R 9 -R 14 and R N have the meanings as defined herein:
- L represents -CH 2 CO-NH-, -CH 2 CO-NCH 3 -, -CH 2 CO-NH-CH 2 -, or -CH 2 CO-NH-CH(CH 3 )-.
- L represents -L 1 -L 2 -;
- L 1 represents -CH 2 - -CH 2 CH 2 - -CH 2 CH 2 CH 2 -, -CH 2 CO- or -CH 2 CH 2 CO-;
- L 2 represents a bond, -NR N1 -, -NR N1 CH 2 -, -NR N1 CH 2 CH 2 -, or -NR N1 CH(CH 3 )-;
- R 1 represents or and R 2 , R 3 , R 5 - R 7 , and R N1 have the meanings as defined above.
- L represents -L 1 - or -L 1 -L 2 -; preferably -L 1 -L 2 -; L 1 represents -CH 2 - -CH 2 CH 2 -, -CH 2 CH 2 CH 2 -, -CH 2 CO-, or -CH 2 CH 2 CO-;
- L 2 represents a bond, -NR N1 -, -NR N1 CH 2 -, -NR N1 CH 2 CH 2 -, or -NR N1 CH(CH 3 )-;
- R 1 represents and R 2 , R 3 , R 5 - R 7 , and R N1 have the meanings as defined above.
- R 2 , R 3 , and R 5 - R 7 have the meanings as defined above.
- L represents -L 1 - or -L 1 -L 2 -; preferably -L 1 -L 2 -;
- L 1 represents -CH 2 - -CH 2 CH 2 - -CH 2 CH 2 CH 2 - -CH 2 CO- or -CH 2 CH 2 CO-;
- L 2 represents a bond, -NR N1 - -NR N1 CH 2 - -NR N1 CH 2 CH 2 - or -NR N1 CH(CH 3 )-; wherein the unsubstituted bicyclic residues can be substituted with 1 to 5 of the substituents R 9 -R 14 , and R N ; and preferably with 1 to 3 of the substituents R 11 - R 13 , and R 5 - R 14 , R N and R N1 have the meanings as defined herein.
- L represents -L 1 - or -L 1 -L 2 -; preferably -L 1 -L 2 -;
- L 1 represents -CH 2 - -CH 2 CH 2 - -CH 2 CH 2 CH 2 - -CH 2 CO- or -CH 2 CH 2 CO-;
- L 2 represents a bond, -NR N1 - -NR N1 CH 2 - -NR N1 CH 2 CH 2 - or -NR N1 CH(CH 3 )-;
- R 2 represents
- unsubstituted bicyclic residues can be substituted with 1 to 5 of the substituents R 9 -R 14 , and R N ; and preferably with 1 to 3 of the substituents R 11 - R 13 , and R 5 - R 14 , R N and R N1 have the meanings as defined herein.
- L represents -L 1 -L 2 -;
- L 1 represents -CH 2 - or -CH 2 CO-;
- L 2 represents a bond, -NR N1 -, -NR N1 CH 2 -, or -NR N1 CH(CH 3 )-;
- R 1 represents
- L represents -L 1 - or -L 1 -L 2 -; preferably -L 1 -L 2 -;
- L 1 represents -CH 2 -, or -CH 2 CO-;
- L 2 represents a bond, -NR N1 - -NR N1 CH 2 - or -NR N1 CH(CH 3 )-;
- R 2 represents
- L represents most preferably -L 1 -L 2 -; wherein L 1 represents preferably -CH 2 CO- or -CH 2 CH 2 CO-; and more preferably -CH 2 CO-; and L 2 represents -NR N1 - -NR N1 CH 2 - or -NR N1 CH(CH 3 )-; more preferably -NH-, -N(CH 3 )-, -NH-CH 2 -, or -NH-CH(CH 3 )-; still more preferably -NH-, -NH-CH 2 -, or -NH-CH(CH 3 )-; and most preferably -NH-.
- R 2 R 3 R 5 R 6 R 7 , R 8 , R 9 R 10 , R 11 , R 12 , R 13 , R a , R b , R c , R d and L 2 have the same meanings as defined above
- R 5 represents -H, -CH 3 , -CH 2 CH 3 , -CH 2 CH 2 CH 3 , -CH(CH 3 ) 2 , -CH 2 CH 2 CH 2 CH 3 , -CH 2 CH(CH 3 ) 2 , -C(CH 3 ) 3, -cyclo-C 3 H 5 , -cyclo-C 4 H 7 , -CH 2 -cyclo-C 3 H 5 , -CH 2 -cyclo-C 4 H 7 ; -CH 2 Ph, or -Ph;
- R 5 represents -H, -CH 3 , -CH 2 CH 3 , -CH 2 CH 2 CH 3 , -CH(CH 3 ) 2 , -CH 2 CH 2 CH 2 CH 3 , -CH 2 CH(CH 3 ) 2 , -C(CH 3 ) 3, -cyclo-C 3 H 5 , -cyclo-C 4 H 7 , -CH 2 -cyclo-C 3 H 5 ,
- the present invention refers to the compounds selected from the group consisting of: MI-1, MI-2, MI-3, MI-4, MI-5, MI-6, MI-7, MI-8, MI-9, MI-10, MI-11, MI-12, MI-13, MI-14, MI-15, MI-16, MI-17, MI-18, MI-19, MI-20, MI-21, MI-22, MI-23,
- the present invention relates to a method for the synthesis of a compound of formula (I), especially any compound of any one of the formulae (la) - (le):
- a further aspect of the present invention relates to the production of compounds of the formula (lc).
- the method for producing the compound of the formula (lc) comprises the following steps in the following order:
- Step 1C providing a compound 4c
- Step 2C performing coupling reaction of the compound 4c with a compound 5 to obtain a compound 6c
- Step 3C deprotecting an amino protecting group PG 3 to obtain a compound 7c
- Step 4C performing coupling reaction of the compound 7c with a carboxylic acid (R 2 -C02H 8) to produce the compound of the formula (lc) wherein L, R 2 , R 3 , R 5 have the same meanings as defined above above in formula (lc), and PG 3 is an amino protecting group.
- Step 1C ' is carried out before the step 1C: (a) providing a protected aldehyde 1 (b) performing a coupling reaction of the aldehyde 1 with a triphenyl phosphonium ylide 2c to obtain an intermediate compound 3c; or alternatively
- Step 1C '
- Step 1C providing a compound 4c
- Step 2C performing coupling reaction of the compound 4c with a compound 5 to obtain a compound 6c
- Step 3C deprotecting an amino protecting group PG 3 to obtain a compound 7c
- Step 4C performing coupling reaction of the compound 7c with a carboxylic acid (R 2 -C02H 8) to produce the compound of the formula (lc) wherein L, R 2 , R 3 , R 5 have the same meanings as defined above in formula (lc), and PG 1 and PG 3 are amino protecting groups,
- PG 2 is a carboxyl protecting group.
- a further aspect of the present invention relates to the production of compounds of the formula (Id).
- Step 1D providing a compound 4d
- Step 2D performing coupling reaction of the compound 4d with a compound 5 to obtain a compound 6d
- Step 3D deprotecting an amino protecting group PG 3 to obtain a compound 7d
- Step 4D performing coupling reaction of the compound 7d with a carboxylic acid (R 2 -CO 2 H 8) to produce the compound of the formula (Id) wherein L, R 2 , R 3 , R 6 , R 7 have the same meanings as defined above in formula (Id), and PG 3 is an amino protecting group.
- Step 1D ' is carried out before the step 1D: (a) providing a protected aldehyde 1
- Step 1 D '
- Step 1D providing a compound 4d
- Step 2D performing coupling reaction of the compound 4d with a compound 5 to obtain a compound 6d
- Step 3D deprotecting an amino protecting group PG 3 to obtain a compound 7d
- Step 4D performing coupling reaction of the compound 7d with a carboxylic acid (R 2 -CO 2 H 8) to produce the compound of the formula (Id) wherein L, R 2 , R 3 , R 6 , R 7 have the same meanings as defined above in formula (Id), and PG 3 is an amino protecting group.
- a further aspect of the present invention relates to the production of compounds of the formula (le).
- Step 1E providing a compound Step 2E: performing coupling reaction of the compound 4e with a compound 5
- Step 3E deprotecting an amino protecting group PG 3 to obtain a compound 7e
- Step 4E performing coupling reaction of the compound 7e with a carboxylic acid (R 2 -C02H 8) to produce the compound of the formula (le) wherein L, R 2 , R 3 , R 5 have the same meanings as defined above in formula (le), and PG 3 is an amino protecting group.
- Scheme 3 Optionally, Step 1E ' is carried out before the step 1E: (a) providing a protected aldehyde 1
- Step 1 E '
- Step 1E providing a compound 4e
- Step 2E performing coupling reaction of the compound 4e with a compound 5 to obtain a compound 6e
- Step 3E deprotecting an amino protecting group PG 3 to obtain a compound 7e
- Step 4E performing coupling reaction of the compound 7e with a carboxylic acid (R 2 -C02H 8) to produce the compound of the formula (le) wherein L, R 2 , R 3 , R 5 have the same meanings as defined above in formula (le), and PG 3 is an amino protecting group.
- first all protecting groups PG 1 and PG 2 are simultaneously removed and the protecting group PG 3 is selectively introduced.
- PG 1 and PG 3 are same.
- protecting groups refers to commonly used protection groups in organic synthesis, preferably for amino and carboxyl groups.
- PG 1 , PG 3 , and PG 5 preferably are suitable protecting groups for amino groups.
- PG 2 and PG 4 preferably are suitable protecting groups for carboxyl groups.
- PG 1 , PG 3 , and PG 5 may be selected from the group consisting of or comprising: acetyl, benzoyl, benzyloxycarbonyl (Cbz), tert-butylcarbonyl, tert-butyloxycarbonyl (Boc), and fluorenylmethylenoxy group (Fmoc).
- PG 2 and PG 4 may be selected from the group consisting of or comprising: methoxy, ethoxy, isobutoxy, tert-butoxy, benzyloxy; preferably, tert-butoxy group.
- activating reagents are commonly used to activating carboxylic acid (ticianPeptide Coupling Reagents, More than a Letter Soup”, Ayman El-Faham and Fernando Albericio, Chemical Reviews, 2011, 111(11), p.6557- 6602).
- the activation may be introduced separate reaction or in situ reaction.
- any of the following coupling reagent can be used to activate carboxylic acid group: BOP (Benzotriazole-l-yl-oxy-tris-(dimethylamino)-phosphonium hexafluorophosphate), PyBOP (Benzotriazole-1 -yl-oxy-tris-pyrrolidino-phosphonium hexafluorophosphate), AOP (7-(Azabenzotriazol-1-yl)oxy tris(dimethylamino)phosphonium hexafluorophosphate), PyAOP ((7-Azabenzotriazol-1- yloxy)tripyrrolidinophosphonium hexafluorophosphate), TBTU (2-(1 FI-Benzotriazole-1- yl)-1,1,3,3-tetramethylaminium tetrafluoroborate), EEDQ (/V-Ethoxycarbonyl-2 -ethoxy- 1, 2-dihydroquino
- Another aspect of the present invention relates to compounds according to the general formula (I) as medicine as well as their use in medicine. Especially preferred is the use as inhibitors of transglutaminases, in particular transglutaminsase 2 (TG2).
- TG2 transglutaminsase 2
- the compounds of the present invention may form of a pharmacologically acceptable salt with organic or inorganic acids or bases.
- suitable acids for such acid addition salt formation are hydrochloric acid, hydrobromic acid, sulfuric acid, phosphoric acid, acetic acid, citric acid, oxalic acid, malonic acid, salicylic acid, p-aminosalicylic acid, malic acid, fumaric acid, succinic acid, ascorbic acid, maleic acid, sulfonic acid, phosphonic acid, perchloric acid, nitric acid, formic acid, propionic acid, gluconic acid, lactic acid, tartaric acid, hydroxymaleic acid, pyruvic acid, phenylacetic acid, benzoic acid, p-aminobenzoic acid, p-hydroxybenzoic acid, methanesulfonic acid, ethanesulfonic acid, nitrous acid, hydroxyethanesulfonic acid, ethylenesulfonic acid, p
- the salts are prepared by contacting the free base form with a sufficient amount of the desired acid to produce a salt in the conventional manner.
- Preferred is the mesylate salt, hydrochloride salt and the trifluoroacetate salt and especially preferred is the trifluoroacetate salt and the hydrochloride salt.
- salts could also be formed with inorganic or organic bases.
- suitable inorganic or organic bases are, for example, NaOFI, KOFI, NH 4 OH , tetraalkylammonium hydroxide, lysine or arginine and the like.
- Salts may be prepared in a conventional manner using methods well known in the art, for example by treatment of a solution of the compound of the general formula (I) with a solution of an acid, selected out of the group mentioned above.
- novel compounds according to the general formula (I) are used as pharmaceutically active agent, i.e. the compound of the formula (I) is used in medicine.
- the present invention relates to a pharmaceutical composition
- a pharmaceutical composition comprising at least one compound according to the general formula (I), as an active ingredient or a pharmacologically acceptable salts thereof as an active ingredient, together with at least one pharmacologically acceptable carrier, excipient and/or diluent.
- the compounds according to general formula (I) described herein are especially suitable for the treatment and prophylaxis of diseases associated with and/or caused by transglutaminase 2.
- tissue transglutaminase TG 2
- fibrotic disorders are characterized by the accumulation of cross- linked extracellular matrix proteins. Diabetic nephropathy, cystic fibrosis, idiopathic pulmonary fibrosis, kidney fibrosis as well as liver fibrosis belong to the most important fibrotic disorders to be addressed with the compounds disclosed.
- inhibiting refers to the ability of a compound to downregulate, decrease, reduce, suppress, inactivate, or inhibit at least partially the activity of an enzyme, or the expression of an enzyme or protein.
- another aspect of the present invention is the use of the inventive compounds of the general formula (I), or the pharmaceutical composition thereof as described in the treatment or prophylaxis of autoimmune and inflammatory diseases, vascular diseases, fibrotic diseases, liver diseases, cholestatic liver diseases, cancer, neurodegenerative diseases, ocular diseases, and skin disorders.
- Further aspects of the present invention relate to the use of the compounds of general formula (I) for the preparation of a pharmaceutical composition useful for prophylaxis and/or treatment of autoimmune and inflammatory diseases, vascular diseases, fibrotic diseases, liver diseases, cholestatic liver diseases, cancer, neurodegenerative diseases, ocular diseases, and skin disorders.
- a method for preventing and/or treating autoimmune and inflammatory diseases, vascular diseases, fibrotic diseases, liver diseases, cholestatic liver diseases, cancer, neurodegenerative diseases, ocular diseases, and skin disorders comprises administering to a subject, in particular a human, a pharmaceutically effective amount of at least one compound of the general formula (I), to prevent and/or treat said autoimmune and inflammatory diseases, vascular diseases, fibrotic diseases, liver diseases, cholestatic liver diseases, cancer, neurodegenerative diseases, ocular diseases, and skin disorders.
- the autoimmune and inflammatory diseases comprises multiple sclerosis, celiac disease, Duhring-Brocq-disease (dermatitis herpetiformis), gluten ataxia, gluten neuropathy, diabetes, rheumatoid arthritis, Graves' disease, inflammatory bowel disease, systemic lupus erythematosus psoriasis, and gingivitis;
- the vascular diseases comprise atherosclerosis, thrombosis, vascular stiffness;
- the compound of the formula (I), or the pharmaceutical composition thereof is useful in the treatment or prophylaxis of celiac disease.
- the compounds of the general formula (I) can be administered in form of their pharmaceutically active salts, optionally using essentially non-toxic pharmaceutically acceptable carriers, adjuvants or extenders.
- Medications are prepared in a known manner in a conventional solid or fluid carrier or in extenders and a conventional pharmaceutically acceptable adjuvant/expedient in a suitable dose.
- the preferred preparations are provided in an administrable form suitable for oral application, such as pills, tablets, film tablets, coated tablets, capsules and powders.
- Tablets, film tablets, coated tablets, gelatin capsules and opaque capsules are the preferred pharmaceutical formulations.
- Any pharmaceutical compositions contains at least one compound of the general formula (I), and/or pharmaceutically acceptable salts thereof in an amount of 5 mg to 500 mg, preferably 10 mg to 250 mg and most preferred in an amount of 10 to 100 mg per formulation.
- the object of the present invention also includes pharmaceutical preparations for oral, parenteral, dermal, intradermal, intragastric, intracutaneous, intravascular, intravenous, intramuscular, intraperitoneal, intranasal, intravaginal, intrabuccal, percutaneous, rectal, subcutaneous, sublingual, topic, transdermal or inhalative application, containing, in addition to typical vehicles and extenders, a compound of the general formula (I), and/or a pharmaceutically acceptable salt thereof as active component.
- pharmaceutical preparations for oral, parenteral, dermal, intradermal, intragastric, intracutaneous, intravascular, intravenous, intramuscular, intraperitoneal, intranasal, intravaginal, intrabuccal, percutaneous, rectal, subcutaneous, sublingual, topic, transdermal or inhalative application containing, in addition to typical vehicles and extenders, a compound of the general formula (I), and/or a pharmaceutically acceptable salt thereof as active component.
- compositions of the present invention contain one of the compounds of the formula (I) disclosed herein as active component, typically mixed with suitable carrier materials, selected with respect to the intended form of administration, i.e. tablets to be administered orally, capsules (filled either with a solid, a semi-solid or a liquid), powders, orally administrable gels, elixirs, dispersible granulates, syrups, suspensions and the like in accordance with conventional pharmaceutical practices.
- suitable carrier materials selected with respect to the intended form of administration, i.e. tablets to be administered orally, capsules (filled either with a solid, a semi-solid or a liquid), powders, orally administrable gels, elixirs, dispersible granulates, syrups, suspensions and the like in accordance with conventional pharmaceutical practices.
- the compound of the formula (I) can as active agent component be combined with any oral, non-toxic, pharmaceutically acceptable, inert carrier, such as lactose, starch, sucrose, cellulose, magnesium stearate, dicalcium phosphate, calcium sulfate, talc, mannitol, ethyl alcohol (liquid forms) and the like for the oral administration in form of tablets or capsules.
- suitable binders, lubricants, disintegrants and colorants can be added to the mixture if required.
- Powders and tablets can consist of said inert carriers to an extent from about 5% per weight to about 95% per weight of the inventive composition.
- Suitable binders include starch, gelatin, natural sugars, sweeteners made of corn, natural and synthetic gums, such as acacia gum, sodium alginate, carboxymethylcellulose, polyethylene glycol and waxes.
- Possible lubricants for the use in said dosage forms include boric acid, sodium benzoate, sodium acetate, sodium chloride and the like.
- Disintegrants include starch, methylcellulose, cyclodextrins, guar gum and the like. If required, sweeteners and flavor additives and preservatives can also be included.
- compositions of the present invention can be formulated in a form with sustained release to provide a controlled release rate of any one or more components or active components, in order to optimize the therapeutic effect, i.e. the inhibitory activity and the like.
- Suitable dosage forms for sustained release include layered tablets containing layers with varying degradation rates or controlled release polymeric matrices impregnated with the active components and in the form of a tablet or capsule containing such impregnated or encapsulated porous polymeric matrices.
- Preparations in fluid form include solutions, suspensions and emulsions.
- solutions include solutions, suspensions and emulsions.
- exemplary mentioned are water or water propylene glycol solutions for parenteral injections or the addition of sweeteners and opacifiers for oral solutions, suspensions and emulsions.
- Aerosol preparations suitable for inhalation may include solutions and solids in the form of powders which can be combined with a pharmaceutically acceptable carrier, such as a compressed inert gas, e.g. nitrogen.
- a pharmaceutically acceptable carrier such as a compressed inert gas, e.g. nitrogen.
- a low melting wax such as a mixture of fatty acid glycerides, e.g. cocoa butter
- the active component is homogenously dispersed therein by stirring or similar mixing operations.
- the melted homogenous mixture is then poured in fitting forms, cooled and thus hardened.
- preparations in solid form which are to be converted into preparations in fluid form for either oral or parenteral administration shortly before use are included.
- fluid forms include solutions, suspensions and emulsions.
- the compounds of the present invention may be administered via transdermal application.
- the transdermal compositions can have the form of cremes, lotions, aerosols and/or emulsions.
- capsule refers to a special container or casing composed of methylcellulose, polyvinyl alcohols or denatured gelatins or starches, in which the active agents can be enclosed.
- hard shell capsules are prepared from mixtures of bones and porcine skin gelatins having comparatively high gel strength.
- the capsule itself can contain small amounts of colorants, opacifiers, softening agents and preservatives.
- Tablet means a compressed or cast solid dosage form containing the active components with suitable extenders.
- the tablet can be produced by compressing mixtures or granulates obtained by wet granulation, dry granulation or compaction, which are known to the one skilled in the art.
- Oral gels refer to the active components dispersed or solubilized in a hydrophilic semi solid matrix.
- Powders for compositions refer to powder mixtures containing the active components and suitable extenders which can be suspended in water or juices.
- Suitable extenders are substances which usually form the largest part of the composition or dosage form. Suitable extenders include sugars such as lactose, sucrose, mannitol and sorbitol; starches derived from wheat, corn, rice and potatoes; and celluloses such as microcrystalline cellulose.
- the amount of extenders in the composition can range from about 5 to about 95% per weight of the total composition, preferably form about 25 to about 75% per weight and further preferred from about 30 to about 60% per weight.
- disintegrants refers to materials added to the composition in order to support disintegration and release of the medicinal substance.
- Suitable disintegrants include starches, modified starches which are soluble in cold water, such as sodium carboxymethyl starch; natural and synthetic gums such as locust bean gum, caraya, guar gum, tragacanth and agar; cellulose derivatives such as methylcellulose and sodium carboxymethylcellulose, microcrystalline celluloses and crosslinked microcrystalline celluloses such as croscarmellose sodium; alginates such as alginic acid and sodium alginate; clays such as bentonites and foaming mixtures.
- the amount of disintegrants used in the composition can range from about 2 to 20% per weight of the composition and further preferred from about 5 to about 10% per weight.
- Binders characterize substances binding or "gluing" powders to each other and they consequently serve as “glue” in the formulation. Binders add a cohesion starch which is already available in the extenders or the disintegrant. Suitable binders include sugar, such as sucrose; starches derived from wheat, corn, rice and potatoes; natural gums such as acacia gum, gelatin and tragacanth; derivatives of sea weed such as alginic acid, sodium alginate and ammonium calcium alginate, cellulose materials such as methyl cellulose and sodium carboxymethylcellulose and hydroxypropyl methylcellulose, polyvinylpyrrolidone and inorganic compounds, such as magnesium aluminum silicate.
- sugar such as sucrose
- starches derived from wheat, corn, rice and potatoes natural gums such as acacia gum, gelatin and tragacanth
- derivatives of sea weed such as alginic acid, sodium alginate and ammonium calcium alginate
- cellulose materials such as methyl
- the amount of binders in the composition can range from about 2 to about 20% per weight of the total composition, preferably form about 3 to about 10% per weight and further preferred from about 3 to about 6% per weight.
- lubricant refers to a substance added to the dosage form in order to allow for the tablet, granulate, etc. to be released from the casting mold or pressing mold, after compression, by reducing the friction. Suitable lubricants include metallic stearates such as magnesium stearate, calcium stearate or potassium stearate; stearic acid; waxes with high melting points and water soluble lubricants such as sodium chloride, sodium benzoate, sodium acetate, sodium oleate, polyethylene glycols and D,L-leucine.
- lubricants Due to the fact that lubricants have to be present on the surface of the granulates as well as between the granulates and parts of the tablet press they are typically added during the last step prior to compression.
- the amount of lubricants in the composition can range from about 0.2 to about 5% per weight of the total composition, preferably form about 0.5 to about 2% per weight and further preferred from about 0.3 to about 1.5 % per weight.
- Lubricants are materials preventing caking and improving the flow characteristics of granulates so that the flow is smooth and uniform.
- Suitable lubricants include silicon dioxide and talc.
- the amount of lubricants in the composition can range from about 0.1 to about 5 % per weight of the total composition, preferably form about 0.5 to about 2 % per weight.
- Colorants are adjuvants coloring the composition or dosage form.
- Such adjuvants can include colorants having food quality which are adsorbed on a suitable adsorption means, such as clay or aluminum oxide.
- the amount of the colorant used can vary from about 0.1 to about 5% per weight of the composition and preferably from about 0.1 to about 1 % per weight.
- a “pharmaceutically effective amount” of a transglutaminase inhibitor is the amount or activity effective for achieving the desired physiological result, either in cells treated in vitro or in a patient treated in vivo.
- a pharmaceutical effective amount is such an amount which is sufficient for inhibiting, for a certain period of time, one or more of the clinically defined pathological processes associated with transglutaminase 2.
- the effective amount can vary according to the specific compound of the formula (I) and additionally depends on a plurality of factors and conditions related to the subject to be treated and the severity of the disease.
- an inhibitor is to be administered in vivo, factors such as age, weight and health of the patients as well as dose reaction curves and data regarding toxicity obtained from preclinical animal studies are amongst the data to be considered. If the inhibitor in form of the compound of the formula (I) described herein is to be brought in contact with the cells in vivo, a plurality of preclinical in vitro studies would be designed in order to determine parameters such as absorption, half-life, dose, toxicity, etc. Determining a pharmaceutically effective amount for a given pharmaceutically active ingredient is part of the ordinary skills of the one skilled in the art. Examples
- Boc (tert-butoxycarbonyl), BocOSu (N-tert-butoxycarbonyloxy-succinimide) DCM (dichloromethane), DMAP (4-(Dimethylamino)-pyridine), TEA (triethylamine), DMF (dimethylformamide), DMP (Dess-Martin periodiane), DIPEA (N-Ethyldiisopropylamine), Glu (glutamic acid), EDC (1-ethyl-3-(3'-dimethylaminopropyl)carbodiimide), TFA (trifluoroacetic acid), TFIF (tetrahydrofuran), EtOAc (ethyl acetate), FIATU (1- [Bis(dimethylamino)methylene]-1 FI-1 ,2,3-triazolo[4,5-b]pyridinium 3-oxid hexafluorophosphate), FIOBt (hydroxybenzotriazole), MTBE (
- compound MI-10 was performed according to compound MI-1, using 3- methyl-1 H-indole-2-carboxylic acid instead of 1 -methyl-1 H-imidazole-5-carboxylic acid in the final step.
- compound 111-16 was synthesized according to compound MI-1, using 2,5-dibromothiophene-3-carboxylic acid instead of 1 -methyl-1 H-imidazole-5-carboxylic acid in the final step.
- compound MI-22 was synthesized according to compound MI-1, using 1- methyl-1 H-1 ,2,3-triazole-5-carboxylic acid instead of 1 -methyl-1 H-imidazole-5- carboxylic acid in the final step.
- compound MI-36 was performed according to compound MI-1, using 5- (methoxycarbonyl)nicotinic acid instead of 1 -methyl-1 H-imidazole-5-carboxylic acid in the final step.
- compound MI-90 was performed according to compound MI-2, using diethyl (methanesulfonylmethyl)phosphonate instead of (carbomethoxymethylene)triphenylphosphorane (according to ZED755).
- compound MI-109 was performed according to compound MI-91, using 1 -methyl-1 H-pyrazole-5-carboxylic acid instead of 1 -methyl-1 H-imidazole-5-carboxylic acid in the final step.
- compound MI-119 was performed according to compound MI-1, using 1 -methyl-1 H-pyrazole-5-carboxylic acid instead of 1 -methyl-1 H-imidazole-5-carboxylic acid in the final step.
- compound 111-131 was synthesized according to compound MI-79, using 1-(2-bromoethyl)adamantane instead of 1-(bromomethyl)adamantane (according to ZED4893) and 5-tert-butyl-1 H-pyrrole-3-carboxylic acid instead of 3-methyl- benzo[b]furan-2-carboxylic acid in the final step.
- compound 111-132 was synthesized according to compound MI-79, using 1-(3-bromopropyl)adamantane instead of 1-(bromomethyl)adamantane (according to ZED4893) and 4-cyano-1 -methyl-1 H-pyrrole-2-carboxylic acid instead of 3-methyl- benzo[b]furan-2-carboxylic acid in the final step.
- compound 111-148 was performed according to compound MI-75, using 2-chloro-N-cyclohexylacetamide instead of 2-chloro-N,N-dimethylacetamide (according to ZED4684) and 1-bicyclo[1.1.1]pentylamine instead of 2-adamantanamine in step 2 (according to ZED3905) and 1 -ethyl-1 H-indole-2-carboxylic acid instead of 3-methyl- benzo[b]furan-2-carboxylic acid in the final step.
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Epidemiology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Neurology (AREA)
- Biomedical Technology (AREA)
- Neurosurgery (AREA)
- Pain & Pain Management (AREA)
- Psychiatry (AREA)
- Rheumatology (AREA)
- Immunology (AREA)
- Hospice & Palliative Care (AREA)
- Gastroenterology & Hepatology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
- Enzymes And Modification Thereof (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Priority Applications (21)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| PE2023003550A PE20240892A1 (es) | 2021-06-30 | 2022-06-30 | Inhibidores de transglutaminasas |
| IL309077A IL309077A (en) | 2021-06-30 | 2022-06-30 | Transglutaminase inhibitors |
| SI202230066T SI4192812T1 (sl) | 2021-06-30 | 2022-06-30 | Zaviralci transglutaminaz |
| DK22741485.1T DK4192812T3 (da) | 2021-06-30 | 2022-06-30 | Transglutaminase-inhibitorer |
| PL22741485.1T PL4192812T3 (pl) | 2021-06-30 | 2022-06-30 | Inhibitory transglutaminaz |
| FIEP22741485.1T FI4192812T3 (fi) | 2021-06-30 | 2022-06-30 | Transglutaminaasien estäjiä |
| HRP20241589TT HRP20241589T1 (hr) | 2021-06-30 | 2022-06-30 | Inhibitori transglutaminaza |
| CA3231327A CA3231327A1 (en) | 2021-06-30 | 2022-06-30 | Inhibitors of transglutaminases |
| LTEPPCT/EP2022/068212T LT4192812T (lt) | 2021-06-30 | 2022-06-30 | Transgliutaminazės inhibitoriai |
| EP22741485.1A EP4192812B1 (en) | 2021-06-30 | 2022-06-30 | Inhibitors of transglutaminases |
| RS20241297A RS66209B1 (sr) | 2021-06-30 | 2022-06-30 | Inhibitori transglutaminaza |
| CA3166252A CA3166252C (en) | 2021-06-30 | 2022-06-30 | Inhibitors of transglutaminases |
| CN202280045269.4A CN117561240B (zh) | 2021-06-30 | 2022-06-30 | 转谷氨酰胺酶的抑制剂 |
| JP2023581052A JP2024528557A (ja) | 2021-06-30 | 2022-06-30 | トランスグルタミナーゼ阻害剤 |
| CA3231322A CA3231322A1 (en) | 2021-06-30 | 2022-06-30 | Inhibitors of transglutaminases |
| MX2023015096A MX2023015096A (es) | 2021-06-30 | 2022-06-30 | Inhibidores de transglutaminasas. |
| ES22741485T ES2994247T3 (en) | 2021-06-30 | 2022-06-30 | Inhibitors of transglutaminases |
| US18/573,802 US20240317708A1 (en) | 2021-06-30 | 2022-06-30 | Inhibitors of transglutaminases |
| AU2022301517A AU2022301517A1 (en) | 2021-06-30 | 2022-06-30 | Inhibitors of transglutaminases |
| KR1020237044976A KR20240035404A (ko) | 2021-06-30 | 2022-06-30 | 트랜스글루타미나제 억제제 |
| CONC2024/0000832A CO2024000832A2 (es) | 2021-06-30 | 2024-01-29 | Inhibidores de transglutaminasas |
Applications Claiming Priority (10)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP21182956.9 | 2021-06-30 | ||
| EP21182956 | 2021-06-30 | ||
| EP21183316 | 2021-07-01 | ||
| EP21183316.5 | 2021-07-01 | ||
| US202163217783P | 2021-07-02 | 2021-07-02 | |
| US63/217,783 | 2021-07-02 | ||
| EPPCT/EP2021/086674 | 2021-12-17 | ||
| PCT/EP2021/086674 WO2023110138A1 (en) | 2021-12-17 | 2021-12-17 | Inhibitors of transglutaminases |
| EPPCT/EP2022/065437 | 2022-06-07 | ||
| EP2022065437 | 2022-06-07 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| WO2023275333A1 true WO2023275333A1 (en) | 2023-01-05 |
Family
ID=99799108
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| PCT/EP2022/068212 Ceased WO2023275333A1 (en) | 2021-06-30 | 2022-06-30 | Inhibitors of transglutaminases |
| PCT/EP2022/068217 Ceased WO2023275337A1 (en) | 2021-06-30 | 2022-06-30 | Inhibitors of transglutaminases |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| PCT/EP2022/068217 Ceased WO2023275337A1 (en) | 2021-06-30 | 2022-06-30 | Inhibitors of transglutaminases |
Country Status (21)
Cited By (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US12172992B2 (en) | 2022-03-22 | 2024-12-24 | Abbvie Inc. | Pyrimidines for degrading Bruton's tyrosine kinase |
Families Citing this family (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP4637764A1 (en) | 2023-12-22 | 2025-10-29 | Zedira GmbH | Oxo-pyridine derivatives as inhibitors of transglutaminases for use in the treatment of pulmonary fibrosis |
Citations (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US9434763B2 (en) | 2012-07-17 | 2016-09-06 | Zedira Gmbh | Derivatives of pyridinone as inhibitors for tissue transglutaminase |
| WO2020033784A1 (en) * | 2018-08-10 | 2020-02-13 | Sitari Pharma, Inc. | Transglutaminase 2 (tg2) inhibitors |
| US11072634B2 (en) | 2016-12-27 | 2021-07-27 | Zedira Gmbh | Inhibitors of transglutaminases |
Family Cites Families (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DE10054687A1 (de) * | 2000-11-03 | 2002-05-16 | N Zyme Biotec Gmbh | Inhibitoren von Transglutaminasen |
| EP1395257A1 (en) * | 2001-06-12 | 2004-03-10 | Elan Pharmaceuticals, Inc. | Macrocycles useful in the treatment of alzheimer's disease |
| GB201218084D0 (en) * | 2012-10-09 | 2012-11-21 | Univ Aston | Novel compounds and methods for use in medicine |
| IL309476A (en) * | 2021-06-30 | 2024-02-01 | Zedira Gmbh | Transglutaminase inhibitors |
| PL4192813T3 (pl) * | 2021-06-30 | 2024-12-23 | Zedira Gmbh | Inhibitory transglutaminaz |
-
2022
- 2022-06-30 DK DK22741485.1T patent/DK4192812T3/da active
- 2022-06-30 WO PCT/EP2022/068212 patent/WO2023275333A1/en not_active Ceased
- 2022-06-30 SI SI202230066T patent/SI4192812T1/sl unknown
- 2022-06-30 IL IL309077A patent/IL309077A/en unknown
- 2022-06-30 FI FIEP22741485.1T patent/FI4192812T3/fi active
- 2022-06-30 EP EP22741485.1A patent/EP4192812B1/en active Active
- 2022-06-30 LT LTEPPCT/EP2022/068212T patent/LT4192812T/lt unknown
- 2022-06-30 JP JP2023581052A patent/JP2024528557A/ja active Pending
- 2022-06-30 RS RS20241297A patent/RS66209B1/sr unknown
- 2022-06-30 PE PE2023003550A patent/PE20240892A1/es unknown
- 2022-06-30 CN CN202280045269.4A patent/CN117561240B/zh active Active
- 2022-06-30 ES ES22741485T patent/ES2994247T3/es active Active
- 2022-06-30 US US18/573,802 patent/US20240317708A1/en active Pending
- 2022-06-30 WO PCT/EP2022/068217 patent/WO2023275337A1/en not_active Ceased
- 2022-06-30 HR HRP20241589TT patent/HRP20241589T1/hr unknown
- 2022-06-30 AU AU2022301517A patent/AU2022301517A1/en active Pending
- 2022-06-30 HU HUE22741485A patent/HUE069300T2/hu unknown
- 2022-06-30 MX MX2023015096A patent/MX2023015096A/es unknown
- 2022-06-30 PL PL22741485.1T patent/PL4192812T3/pl unknown
-
2023
- 2023-12-28 CL CL2023003951A patent/CL2023003951A1/es unknown
-
2024
- 2024-01-29 EC ECSENADI20247534A patent/ECSP24007534A/es unknown
- 2024-01-29 CO CONC2024/0000832A patent/CO2024000832A2/es unknown
Patent Citations (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US9434763B2 (en) | 2012-07-17 | 2016-09-06 | Zedira Gmbh | Derivatives of pyridinone as inhibitors for tissue transglutaminase |
| US11072634B2 (en) | 2016-12-27 | 2021-07-27 | Zedira Gmbh | Inhibitors of transglutaminases |
| WO2020033784A1 (en) * | 2018-08-10 | 2020-02-13 | Sitari Pharma, Inc. | Transglutaminase 2 (tg2) inhibitors |
Non-Patent Citations (6)
| Title |
|---|
| AYMAN EL-FAHAMFERNANDO ALBERICIO: "Peptide Coupling Reagents, More than a Letter Soup", CHEMICAL REVIEWS, vol. 111, no. 11, 2011, pages 6557 - 6602, XP055708830, DOI: 10.1021/cr100048w |
| BUCHOLD, CHILS, MGERLACH, U.WEBER, J.PELZER, CHEIL, AAESCHLIMANN, D.PASTERNACK, R: "Features of ZED1227: The First-In-Class Tissue Transglutaminase Inhibitor Undergoing Clinical Evaluation for the Treatment of Celiac Disease", CELLS, vol. 11, 2022, pages 1667, Retrieved from the Internet <URL:https:/Idoi.org/10.3390/cells11101667> |
| J.M. WODZINSKA, MINI-REVIEWS IN MEDICAL CHEMISTRY, vol. 5, 2005, pages 279 - 292 |
| SUBBAIAH ET AL., J. MED. CHEM., vol. 64, no. 19, 2021, pages 14046 - 14128 |
| TSE EDWIN G. ET AL: "Nonclassical Phenyl Bioisosteres as Effective Replacements in a Series of Novel Open-Source Antimalarials", vol. 63, no. 20, 17 July 2020 (2020-07-17), US, pages 11585 - 11601, XP055933193, ISSN: 0022-2623, Retrieved from the Internet <URL:http://pubs.acs.org/doi/pdf/10.1021/acs.jmedchem.0c00746> DOI: 10.1021/acs.jmedchem.0c00746 * |
| TSE ET AL., J. MED. CHEM., vol. 63, 2020, pages 11585 - 11601 |
Cited By (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US12172992B2 (en) | 2022-03-22 | 2024-12-24 | Abbvie Inc. | Pyrimidines for degrading Bruton's tyrosine kinase |
Also Published As
| Publication number | Publication date |
|---|---|
| CN117561240B (zh) | 2025-08-15 |
| LT4192812T (lt) | 2024-12-10 |
| US20240317708A1 (en) | 2024-09-26 |
| EP4192812A1 (en) | 2023-06-14 |
| AU2022301517A1 (en) | 2023-12-14 |
| ES2994247T3 (en) | 2025-01-21 |
| CN117561240A (zh) | 2024-02-13 |
| JP2024528557A (ja) | 2024-07-30 |
| WO2023275337A1 (en) | 2023-01-05 |
| PL4192812T3 (pl) | 2025-02-03 |
| RS66209B1 (sr) | 2024-12-31 |
| SI4192812T1 (sl) | 2025-02-28 |
| HUE069300T2 (hu) | 2025-02-28 |
| ECSP24007534A (es) | 2024-04-30 |
| CL2023003951A1 (es) | 2024-06-07 |
| CO2024000832A2 (es) | 2024-05-10 |
| HRP20241589T1 (hr) | 2025-01-31 |
| PE20240892A1 (es) | 2024-04-24 |
| MX2023015096A (es) | 2024-03-14 |
| IL309077A (en) | 2024-02-01 |
| EP4192812B1 (en) | 2024-09-04 |
| DK4192812T3 (da) | 2024-09-16 |
| FI4192812T3 (fi) | 2024-11-29 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| EP4192813B1 (en) | Inhibitors of transglutaminases | |
| CN109379891B (zh) | 作为激肽释放酶抑制剂的化合物的多晶型 | |
| CN102482228A (zh) | 含有内酰胺或苯磺酰胺化合物的药物 | |
| DK2797892T3 (en) | Pyridinonderivat as vævstransglutaminaseinhibitorer | |
| AU2022301517A1 (en) | Inhibitors of transglutaminases | |
| EP4192814B1 (en) | Inhibitors of transglutaminases | |
| JP2007507473A (ja) | ソマトスタチン受容体1及び/又は4選択的アゴニスト及びアンタゴニスト | |
| CN107840826A (zh) | 1h‑吲唑类衍生物及其作为ido抑制剂的用途 | |
| HK40095238B (en) | Inhibitors of transglutaminases | |
| HK40095238A (en) | Inhibitors of transglutaminases | |
| HK40095266B (en) | Inhibitors of transglutaminases | |
| HK40095266A (en) | Inhibitors of transglutaminases | |
| CA3231327A1 (en) | Inhibitors of transglutaminases | |
| TWI400240B (zh) | 具有抗血栓阻塞活性之亞胺基咪唑并吡啶衍生物 | |
| KR20240035404A (ko) | 트랜스글루타미나제 억제제 | |
| EA048648B1 (ru) | Ингибиторы трансглутаминаз | |
| CA3166252A1 (en) | Inhibitors of transglutaminases | |
| HK40095264B (en) | Inhibitors of transglutaminases | |
| HK40095264A (en) | Inhibitors of transglutaminases | |
| EA048609B1 (ru) | Ингибиторы трансглутаминаз | |
| CA2545478A1 (en) | Indolyl-thieno'3,4-bipyrazin-3-one derivatives useful for treating hyper-proliferative disorders and diseases associated with angiogenesis |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| 121 | Ep: the epo has been informed by wipo that ep was designated in this application |
Ref document number: 22741485 Country of ref document: EP Kind code of ref document: A1 |
|
| ENP | Entry into the national phase |
Ref document number: 2022741485 Country of ref document: EP Effective date: 20230307 |
|
| WWE | Wipo information: entry into national phase |
Ref document number: 2022301517 Country of ref document: AU Ref document number: AU2022301517 Country of ref document: AU |
|
| WWE | Wipo information: entry into national phase |
Ref document number: 309077 Country of ref document: IL |
|
| WWE | Wipo information: entry into national phase |
Ref document number: 806198 Country of ref document: NZ |
|
| WWE | Wipo information: entry into national phase |
Ref document number: MX/A/2023/015096 Country of ref document: MX |
|
| ENP | Entry into the national phase |
Ref document number: 2022301517 Country of ref document: AU Date of ref document: 20220630 Kind code of ref document: A |
|
| WWE | Wipo information: entry into national phase |
Ref document number: 12023553449 Country of ref document: PH |
|
| WWE | Wipo information: entry into national phase |
Ref document number: 202280045269.4 Country of ref document: CN |
|
| WWE | Wipo information: entry into national phase |
Ref document number: 202393431 Country of ref document: EA |
|
| WWE | Wipo information: entry into national phase |
Ref document number: 2301008535 Country of ref document: TH Ref document number: P6003373/2023 Country of ref document: AE |
|
| ENP | Entry into the national phase |
Ref document number: 2023581052 Country of ref document: JP Kind code of ref document: A |
|
| WWE | Wipo information: entry into national phase |
Ref document number: 003550-2023 Country of ref document: PE |
|
| WWE | Wipo information: entry into national phase |
Ref document number: DZP2024000001 Country of ref document: DZ |
|
| REG | Reference to national code |
Ref country code: BR Ref legal event code: B01A Ref document number: 112023027611 Country of ref document: BR |
|
| WWE | Wipo information: entry into national phase |
Ref document number: 202417002405 Country of ref document: IN |
|
| WWE | Wipo information: entry into national phase |
Ref document number: NC2024/0000832 Country of ref document: CO |
|
| NENP | Non-entry into the national phase |
Ref country code: DE |
|
| ENP | Entry into the national phase |
Ref document number: 112023027611 Country of ref document: BR Kind code of ref document: A2 Effective date: 20231227 |
|
| WWP | Wipo information: published in national office |
Ref document number: NC2024/0000832 Country of ref document: CO |
|
| WWE | Wipo information: entry into national phase |
Ref document number: P-2024/1297 Country of ref document: RS |
|
| WWG | Wipo information: grant in national office |
Ref document number: P-2024/1297 Country of ref document: RS |
|
| WWG | Wipo information: grant in national office |
Ref document number: 202280045269.4 Country of ref document: CN |